Eisai Begins Free Supply of Diethylcarbamazine In Line With Its

Eisai Begins Free Supply of Diethylcarbamazine In Line With Its Global
Commitment to Eliminate Lymphatic Filariasis 
Tokyo, Oct 29, 2013 - (JCN Newswire) -  Eisai Co., Ltd. announced today that it
has begun the free supply of diethylcarbamazine citrate (DEC) 100 mg tablets
produced at its Vizag Plant in
India to the World Health Organization (WHO) in line with its commitment to
help WHO in its global effort to eliminate lymphatic filariasis in targeted
developing and emerging countries. 
The Pacific island nations of Papua New Guinea, Kiribati, Tuvalu and Fiji have
been confirmed as the first countries to receive the initial shipment. An
estimated 6.25 million people living in at-risk communities will benefit from
mass drug administration (MDA) programs. 
Eisai is an active partner and signatory to the London Declaration, a global
public-private partnership that aims to eliminate ten neglected tropical
diseases (NTDs), including lymphatic filariasis, by 2020. As part of its
commitment to this global initiative, Eisai has agreed to supply for free 2.2
billion DEC tablets to WHO
for use in national MDA programs. 
Lymphatic filariasis, commonly known as elephantiasis, is a parasitic disease
that is transmitted to humans by the bite of a mosquito. Once transmitted, it
can cause lymphatic dysfunction and lead toserious manifestations such as
lymphoedema, causing painful and disfiguring manifestations of the disease.
Currently, an estimated 120 million people are already affected and more than
1.4 billion people
worldwide are at risk of this disease. High-quality DEC (one of the drugs used
to treat lymphatic filariasis)is in short supply worldwide and is not easily
accessible to at-risk populations in lymphaticfilariasis-endemic countries.
This poses a major obstacle for eliminating the disease. Having started the
production of DEC at its Vizag Plant in India in August 2013, Eisai has now
begun to provide a steady supply of DEC tablets over a seven-year period from
2013 to 2020 for distribution through WHO's MDA programs to some 250
million people living in at-risk communities in 26 targeted countries(2). 
Eisai believes that contributing to the improvement of global health and
access to medicines in developing countries is a form of long-term investment
that contributes to the economic growth of these countries. 
The company remains actively committed to addressing overall issues in global
health, including NTDs, in order to further increase the benefits provided to
patients and their families worldwide. 
Notes:
(1) WHO Preventive Chemotherapy and Transmission Control (PCT) Databank (as of
2012)
http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/
(2) Bangladesh, Brazil, Comoros, Dominican Republic, Egypt, Fiji, French
Polynesia, Gambia, Guyana, Haiti, Indonesia, Kenya, Kiribati, Federated States
of Micronesia, Lao PDR, Madagascar, Malaysia, Papua New Guinea, Myanmar, Nepal,
Samoa, Sao Tome and Principe, Timor-Leste, Tuvalu, Zambia, Zimbabwe 
About Eisai 
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care
(hhc) company that discovers, develops and markets products throughout the
world. Eisai focuses its efforts in three therapeutic areas: integrative
neuroscience, including neurology and psychiatric medicines; integrative
oncology, which encompasses oncotherapy and supportive-care treatments; and
vascular/immunological reaction. Through a global network of research
facilities, manufacturing sites and marketing subsidiaries, Eisai actively
participates in all aspects of the worldwide healthcare system. For more
information about Eisai Co., Ltd., please visit www.eisai.com. 
Contact: 
Eisai Co., Ltd.
+81-(0)3-3817-5120 
Copyright 2013 JCN Newswire. All rights reserved. www.japancorp.net 
Provider ID: 00027904
 
 
Press spacebar to pause and continue. Press esc to stop.